


CELESTIAL BIOLABS LIMITED
Plot No.59, Road No.12, TSIC Tech Park, IDA Nacharam, Hyderabad-500 076
AUDITED FINANCIAL RESULTS FOR THE PERIOD ENDED 31ST MARCH,2019


SL.NO.	PARTICULARS	Rs In Lacs				
		Quarter Ended			Year Ended	
		31.03.2019 (audited)	31.12.2018 (Unaudited)	31.03.2018 (audited)	31.03.2019 (audited)	31.03.2018 (audited)
I	Income from operations					
	a) Revenue from operations	298.00	1,246.74	1,635.74	4,897.42	4,281.46
	b) Other Income	34.95	-	-	35.65	0.04
	Total income	332.95	1,246.74	1,635.74	4,933.07	4,281.50
II	Expenditure					
	a) Cost of raw and packing materials consumed	17.16	3.84	-	51.40	10.80
	b) Purchase of Traded Products	145.56	891.89	991.19	3,070.24	2,490.61
	c) Changes of Inventories of Finished Goods, Work in Progress and Stock in Trade	(411.81)	80.27	90.10	(251.56)	366.59
	d) Employee Benefits Expense	17.86	-	26.07	148.19	63.40
	e) Depreciation and amortization	370.71	192.58	191.81	944.13	769.54
	g) Finance Cost	97.09	14.27	2.19	125.05	2.54
	h) Other Expenses	150.25	24.83	87.78	705.27	167.16
	Total expenses	386.82	1,207.68	1,389.14	4,792.71	3,870.64
III	Profit / (Loss) before exceptional and extra ordinary items (I-II)	(53.87)	39.06	246.60	140.36	410.86
IV	Exceptional items	-	-	-	-	-
V	Profit / (Loss) before tax (III - IV)	(53.87)	39.06	246.60	140.36	410.86
VI	Tax expense	-	-	60.22	(143.17)	78.29
VII	Net Profit / (Loss) for the period (V-VI)	(53.87)	39.06	186.38	(2.81)	332.57
VIII	Other Comprehensive Income,	-	-	(13.06)	-	(13.06)
	Total Other Comprehensive Income, net of Tax	-	-	(13.06)	-	(13.06)
IX	Total Comprehensive Income for the period	(53.87)	39.06	199.44	(2.81)	345.63
X	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	2,258.63	2,258.63	2,258.63	2,258.63	2,258.63
XI	Earning Per Share for the Period					
	Basic	-0.24	0.17	0.88	-0.01	1.53
	Diluted	-0.24	0.17	0.88	-0.01	1.53

For CELESTIAL BIOLABS LTD

Managing Director

Notes

- 1) The Statement has been reviewed by the Audit Committee and approved by the Board of Directors at it's meeting held on 04.06.2019
- 2) Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement Principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules , 2015 as amended from time to time.
- 3) The Financial results and other financial information for the quarter ended 31st March,2019 and year to date has been compiled by the management as per Ind AS, after excercising necessary due deligence , to ensure that the financial results provide true and fair view of the results in accordance with Ind AS. This information has not been subject to any limited review or audit. Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE) and are available in Company's website www.celestialbiolabs.com

HYDERABAD
Date: 04.06.2019

For CELESTIAL BIOLABS LTD

Managing Director
MANAGING DIRECTOR

Balance sheet as at 31 March,2019

Particulars	March 31, 2019	March 31, 2018
ASSETS		
Non- current assets		
Property, Plant & Equipment		
i) Tangible assets	1,215.70	1,284.34
ii) Other Intangible assets	3,935.77	4,025.55
iii) Capital work - in - progress	2,955.81	2,955.81
ii) Intangible assets under developments	1,567.81	488.25
Financial Assets - Other financial assets	-	30.10
	9,675.09	8,784.04
Current Assets		
Inventories & Traded Goods	613.50	395.77
Financial Assets		
i) Trade receivables	1,563.65	2,076.91
ii) Cash and cash equivalents	5.04	0.99
iii) Short-term loans and advances	75.85	67.69
Other Current Assets	-	70.05
	2,258.04	2,611.41
TOTAL	11,933.13	11,395.45
EQUITY AND LIABILITIES		
EQUITY		
Equity share capital	2,258.63	2,258.63
Other Equity	7,968.67	7,971.47
Money received against share warrants	-	-
	10,227.30	10,230.10
Non- current liabilities		
Financial Liabilities		
Long-term borrowings	781.65	482.00
Deferred tax liabilities (net)	140.52	-2.65
	922.17	479.35
Current liabilities		
Financial Liabilities		
Trade payables	55.79	43.36
b) Other current liabilities	579.56	487.59
c) Short-term provisions	148.31	155.05
	783.66	686.00
TOTAL	11,933.13	11,395.45
Significant Accounting Policies		
Notes to the Financial Statements	-0.00	-0.00

For and on Behalf of the Board


 Dr.A.N.Singh
 Managing Director



Statement of Profit and Loss For the year ended 31st March, 2019

Particulars	31.03.2019	31.03.2018
INCOME		
Revenue from operations	4,897.42	4,281.46
Other income	35.65	0.04
Total revenue	4,933.07	4,281.50
EXPENSES		
Cost of materials consumed	51.40	10.80
Purchase of Stock-in-Trade	3,070.24	2,490.61
Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(251.56)	366.59
Employee benefits expenses	148.19	63.40
Finance costs	125.05	2.54
Depreciation and amortisation expense	944.13	769.54
Other expenses	705.27	167.16
Total expenses	4,792.71	3,870.64
Profit/(loss) before Exceptional Items and Tax	140.36	410.86
Exceptional Items	-	-
Profit Before Tax for the year	140.36	410.86
Tax Expense		
Current Tax	-	78.29
Deffered Tax	-143.17	13.06
Profit/(loss) for the period from continuing operations	-2.81	345.64
Profit/(loss) for from discontinuing operations	-	-
Tax expences of discontinuing operations	-	-
Profit/(loss) for from discontinuing operations (After Tax)	-	-
	-2.81	345.64
Other comprehensive Income		
A (i) Items that will not be reclassified to profit or Loss		
Other Comprehensive Income		-
Total Comprehensive Income for the year	-2.81	345.64
Earnings per Equity Share of face value of ` 10 each		
Basic (In Rs.)	-0.01	1.53
Diluted (In Rs)	-0.01	1.53
Significant Accounting Policies		
Notes to the Financial Statements		

For and on Behalf of the Board


Dr. A.N. Singh
Managing Director


Amit Kumar Singh
Director



Place: Hyderabad
Date: 04.06.2019



B V SWAMI & CO.,
CHARTERED ACCOUNTANTS

Flat No. 101, Sridevi Apartments,
Hindi Nagar Colony, Punjagutta,
Hyderabad - 500 082.
Ph : 040-23350300
E-mail : cachandrasedkharv@gmail.com
girishputha@gmail.com

Auditors Report on Quarterly Financial Results and year to date results of M/s. CELESTIAL BIOLABS LIMITED pursuant to the regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.

To

Board of Directors of CELESTIAL BIOLABS LIMITED

We have audited the accompanying statement of quarterly stand alone IND AS financial results of CELESTIAL BIOLABS LIMITED ("the Company") for the quarter ended 31st March 2019 and the year to date results for the period 1st April 2018 to 31st March 2019, attached herewith, being submitted by the Company pursuant to the requirement of Regulations 33 of the securities and exchange Board of India (Listing Obligations and Disclosure Requirement) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the companies management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (IND AS 34) for interim financial reporting, prescribed, under section 133 of the companies act 2013 read with relevant rules issued there under 'or by the institute of chartered accountants of India, as applicable and other accounting principles generally accepted in india.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the IND AS financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as standalone IND AS financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us, these quarterly stand alone IND AS financial results as well as the year to date results subject to the matters discussed in Basis for Qualified Opinion paragraph below,

a. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016: and





b. gives a true and fair view of net loss and other financial information for the quarter ended 31st March 2019 as well as the year to date results for the period from 1st April 2018 to 31st March 2019.

Basis for Qualified Opinion

In view of the IND AS 36 Impairment of Assets, the management of the company has to demonstrate how the Intangible Asset will generate the probable future economic benefits, also has to allocate the resources to complete, use and obtain the benefit from the Intangible Asset. In the absence of providing the report containing the future economic benefits and compliance of matters stated in the above sentence, we are unable to comment on the carrying value of Rs. 4025.55 Lakhs of such Intangible asset.


EMPHASIS OF MATTER

1. The Company has long-term borrowings with State bank of India and the bank sanctioned the OTS (which has expired) for Rs. 548.06 lakhs. The opening balance of loan of Rs.460.00 lakhs increased to OTS amount by charging the interest.
2. The company has loan (termed as grant) outstanding with DSIR (Department of Scientific & Industrial Research, Ministry of Science and Technology) of Rs.55.00 lakhs at the beginning of the year, during the year the company has reduced the liability to Rs.22.50 lakhs by recognising the difference as other income of Rs.32.50 lakhs. The management have stated that they have sent the proposal to the concerned authorities and the proposal is in the final stage of approval and the management is confident to get the favourable decision regarding the same.

Our opinion is not modified in respect of the above said matters.

For B V SWAMI & Co.,
Chartered Accountants
Firm Reg. No: 009151S


CA. Chandrasekhar V.
Partner
M.No.223399



Place: Hyderabad
Date: 04-06-2019